MAP2K7 and neoplasm: Indeed, BRAFi (dabrafenib and vemurafenib), alone or more frequently in combination with MEK inhibitors (trametinib and cobimetinib), showed encouraging results with ≥80% of reduction of tumour volume in more than 60% of reported cases.